Needham Reiterates Buy on Revance Therapeutics, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has reiterated a Buy rating on Revance Therapeutics (NASDAQ:RVNC) and maintained a $12 price target.
August 09, 2024 | 12:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Serge Belanger has reiterated a Buy rating on Revance Therapeutics and maintained a $12 price target.
The reiteration of a Buy rating and maintenance of a $12 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100